Emerald Health Expands into Analytical Testing and Import/Export
August 7th, 2018
Exclusive, News, Top Story
Canada’s cannabis market is projected to reach more than C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis later this year. In addition to cultivation, this growth is fueling many other areas of the industry, including product development, analytical testing, and imports and exports. Investors may want to keep an eye on these areas as potential opportunities ahead.
Emerald Health Therapeutics Inc. (TSX-V: EMH) (OTCQX: EMHTF) recently acquired a dealer license from Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) that enables it to compete in these areas.
Licensed Producer vs. Licensed Dealer
Most investors are familiar with Licensed Producers, or LPs, under the Access to Cannabis for Medical Purposes Regulations, or ACMPR. LPs are permitted to cultivate, process, and sell medical (and soon recreational) cannabis into the legal market, as well as export cannabis flower to international markets. However, there are some important limitations to the license that inhibit product development and import/export opportunities.
Licensed Dealers, or LDs, under the Canadian Controlled Drugs and Substances Act step in to fill some of these gaps. LDs are permitted to import and export cannabis oils and resins, as well as prepare the manipulation, formulation, dosage form, strength or package size of cannabis products, including mixtures with other additives, controlled substances, and non-controlled substances. These capabilities make the licenses extremely valuable.
There are less than 50 licensed dealers throughout the country compared to more than 100 licensed producers authorized by Health Canada. Many licensed producers have been acquiring dealer licenses as a way to export higher value medical cannabis extracts rather than just cannabis flower. For example, Canopy Growth Corp.’s (TSX: WEED) Tweed Inc. acquired a dealer license back in December 2016.
Recent deals highlight the value of a dealer license. In May, 2018 Auxly Cannabis Group Inc. (TSX-V: XLY)(OTCQX: CBWTF), formerly known as Cannabis Wheaton, announced the acquisition of DoseCann Inc., a late stage licensed dealer applicant based on Prince Edward Island. The stock transaction carries a price tag of up to $38 million, with a little wiggle room based on milestones achieved.
In June, Aurora Cannabis Inc. (TSX: AB) (OTCQB: ACBFF) announced a proposed stock transaction worth $115 million to acquire Anandia Laboratories Inc. Based in British Columbia, Anandia is recognized as an industry leader, one of the largest and most established cannabis labs in the country.
Emerald Health Acquires a Dealer License
Emerald Health recently became one of the few licensed producers with a dealer license after acquiring the remaining shares of Northern Vine Canada Inc. from Abattis Bioceuticals Corp. for $2 million in cash and $4 million in stock. Northern Vine will continue to operate independently and is committed to serving all of its clients, including patient-growers and licensed producers that could potentially compete with Emerald.
“The acquisition of Northern Vine allows us to leverage its dealer license and research and development facility to advance our research plans to develop cannabis formulations supporting new products for both recreational purposes and to treat a broad spectrum of human conditions and diseases,” said Emerald Health CEO Chris Wagner. “The dealer license would also enable Emerald to cost-effectively source non-dried-flower cannabis products from suppliers in other countries.”
The move follows the company’s initial 53 percent investment in Northern Vine back in November 2017 for $2 million. In May 2018, the company increased that investment to 65 percent for an additional $2.75 million. The final acquisition includes the aforementioned payments, as well as a milestone payment in the form of common shares valued at $4 million if Northern Vine or Emerald receive gross revenue of $10 million from Abattis products.
When comparing the Emerald acquisition with those of Aurora and Auxly, noted above, it looks like Emerald got a pretty good deal. Auxly bought an applicant for a dealer license in Prince Edward Island for $38 million, while Aurora bought a larger established lab in BC for $115 million. Emerald’s price tag of $11 – $15 million for an established lab in the licensed producer mecca of BC offers value pretty much any way you look at it.
Emerald Health Therapeutics Inc.’s (TSX-V: EMH) (OTCQX: EMHTF) acquisition of Northern Vine puts it in an exclusive group of licensed producers with dealer licenses. These new capabilities will help supplement the company’s existing cultivation operations that include a 50 percent stake in Pure Sunfarms — and its 1.1 million sq. ft. greenhouse — and its Agro-Biotech operation with a 75,000 sq. ft. facility.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: http://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.